The type B leukemogenic virus truncated superantigen is dispensable for T-cell lymphomagenesis

J Virol. 2003 Mar;77(6):3866-70. doi: 10.1128/jvi.77.6.3866-3870.2003.

Abstract

Type B leukemogenic virus (TBLV) is a variant of mouse mammary tumor virus (MMTV) that causes T-cell lymphomas in mice. We have constructed a TBLV-MMTV hybrid, pHYB-TBLV, in which 756 bp of the C3H MMTV long terminal repeat (LTR) was replaced with 438 bp of the TBLV LTR. Intraperitoneal injection of pHYB-TBLV transfectants consistently resulted in T-cell lymphomas in 50% of injected weanling BALB/c mice with an average latency period of 5.7 (+/- 1.5) months. Transfectants of pHYB-TBLV containing a double-frameshift mutation in the truncated superantigen gene (sag) induced T-cell lymphomas with similar incidences, latency periods, and phenotypes, suggesting that cis-acting elements in the TBLV LTR determine disease specificity.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Female
  • Humans
  • Jurkat Cells
  • Lymphoma, T-Cell / physiopathology*
  • Lymphoma, T-Cell / virology*
  • Male
  • Mammary Tumor Virus, Mouse / genetics
  • Mammary Tumor Virus, Mouse / immunology
  • Mammary Tumor Virus, Mouse / pathogenicity*
  • Mice
  • Mice, Inbred BALB C
  • Mutation*
  • Recombination, Genetic
  • Retroviridae Infections / virology
  • Superantigens / genetics*
  • Superantigens / immunology
  • Terminal Repeat Sequences / genetics
  • Tumor Virus Infections / virology

Substances

  • Superantigens